Literature DB >> 23567617

Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure.

Yuchuan Liu1, A Ray Dillon, Michael Tillson, Catherine Makarewich, Vincent Nguyen, Louis Dell'Italia, Abdel Karim Sabri, Victor Rizzo, Emily J Tsai.   

Abstract

Nitric oxide activation of soluble guanylyl cyclase (sGC) blunts the cardiac stress response, including cardiomyocyte hypertrophy. In the concentric hypertrophied heart, oxidation and re-localization of myocardial sGC diminish cyclase activity, thus aggravating depressed nitric oxide-cyclic guanosine monophosphate (NO-cGMP) signaling in the pressure-overloaded failing heart. Here, we hypothesized that volume-overload differentially disrupts myocardial sGC activity during early compensated and late decompensated stages of eccentric hypertrophy. To this end, we studied the expression, redox state, subcellular localization, and activity of sGC in the left ventricle of dogs subjected to chordal rupture-induced mitral regurgitation (MR). Unoperated dogs were used as Controls. Animals were studied at 4weeks and 12months post chordal rupture, corresponding with early (4wkMR) and late stages (12moMR) of eccentric hypertrophy. We found that the sGC heterodimer subunits relocalized away from caveolae-enriched lipid raft microdomains at different stages; sGCβ1 at 4wkMR, followed by sGCα1 at 12moMR. Moreover, expression of both sGC subunits fell at 12moMR. Using the heme-dependent NO donor DEA/NO and NO-/heme-independent sGC activator BAY 60-2770, we determined the redox state and inducible activity of sGC in the myocardium, within caveolae and non-lipid raft microdomains. sGC was oxidized in non-lipid raft microdomains at 4wkMR and 12moMR. While overall DEA/NO-responsiveness remained intact in MR hearts, DEA/NO responsiveness of sGC in non-lipid raft microdomains was depressed at 12moMR. Caveolae-localization protected sGC against oxidation. Further studies revealed that these modifications of sGC were also reflected in caveolae-localized cGMP-dependent protein kinase (PKG) and MAPK signaling. In MR hearts, PKG-mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP) disappeared from caveolae whereas caveolae-localization of phosphorylated ERK5 increased. These findings show that differential oxidation, re-localization, and expression of sGC subunits distinguish eccentric from concentric hypertrophy as well as compensated from decompensated heart failure.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23567617      PMCID: PMC4064793          DOI: 10.1016/j.yjmcc.2013.03.019

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  50 in total

1.  cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes.

Authors:  Beate Fiedler; Robert Feil; Franz Hofmann; Christian Willenbockel; Helmut Drexler; Albert Smolenski; Suzanne M Lohmann; Kai C Wollert
Journal:  J Biol Chem       Date:  2006-08-29       Impact factor: 5.157

Review 2.  Caveolae as organizers of pharmacologically relevant signal transduction molecules.

Authors:  Hemal H Patel; Fiona Murray; Paul A Insel
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1.

Authors:  Hemal H Patel; Yasuo M Tsutsumi; Brian P Head; Ingrid R Niesman; Michelle Jennings; Yousuke Horikawa; Diane Huang; Ana L Moreno; Piyush M Patel; Paul A Insel; David M Roth
Journal:  FASEB J       Date:  2007-02-01       Impact factor: 5.191

4.  Mitogen-activated protein kinases (p38 and c-Jun NH2-terminal kinase) are differentially regulated during cardiac volume and pressure overload hypertrophy.

Authors:  Somkiat Sopontammarak; Assad Aliharoob; Catherina Ocampo; Rene A Arcilla; Mahesh P Gupta; Madhu Gupta
Journal:  Cell Biochem Biophys       Date:  2005       Impact factor: 2.194

5.  Compensated volume overload increases the vulnerability of heart mitochondria without affecting their functions in the absence of stress.

Authors:  Mariannick Marcil; Alexis Ascah; Jimmy Matas; Sonia Bélanger; Christian F Deschepper; Yan Burelle
Journal:  J Mol Cell Cardiol       Date:  2006-10-24       Impact factor: 5.000

6.  Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.

Authors:  Thomas D Ryan; Emily C Rothstein; Inmaculada Aban; Jose A Tallaj; Ahsan Husain; Pamela A Lucchesi; Louis J Dell'Italia
Journal:  J Am Coll Cardiol       Date:  2007-02-05       Impact factor: 24.094

7.  Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes.

Authors:  Liliana R V Castro; Ignacio Verde; Dermot M F Cooper; Rodolphe Fischmeister
Journal:  Circulation       Date:  2006-05-01       Impact factor: 29.690

8.  Sympathetic activation causes focal adhesion signaling alteration in early compensated volume overload attributable to isolated mitral regurgitation in the dog.

Authors:  Abdelkarim Sabri; Khadija Rafiq; Rachid Seqqat; Mikhail A Kolpakov; Ray Dillon; Louis J Dell'italia
Journal:  Circ Res       Date:  2008-03-20       Impact factor: 17.367

9.  Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.

Authors:  Andreas Knorr; Claudia Hirth-Dietrich; Cristina Alonso-Alija; Michael Härter; Michael Hahn; Yvonne Keim; Frank Wunder; Johannes-Peter Stasch
Journal:  Arzneimittelforschung       Date:  2008

10.  Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway.

Authors:  Marco Mongillo; Carlo G Tocchetti; Anna Terrin; Valentina Lissandron; York-Fong Cheung; Wolfgang R Dostmann; Tullio Pozzan; David A Kass; Nazareno Paolocci; Miles D Houslay; Manuela Zaccolo
Journal:  Circ Res       Date:  2005-12-15       Impact factor: 17.367

View more
  10 in total

1.  Caveolin-3 Overexpression Attenuates Cardiac Hypertrophy via Inhibition of T-type Ca2+ Current Modulated by Protein Kinase Cα in Cardiomyocytes.

Authors:  Yogananda S Markandeya; Laura J Phelan; Marites T Woon; Alexis M Keefe; Courtney R Reynolds; Benjamin K August; Timothy A Hacker; David M Roth; Hemal H Patel; Ravi C Balijepalli
Journal:  J Biol Chem       Date:  2015-07-13       Impact factor: 5.157

2.  Cardiac Tissue Chips (CTCs) for Modeling Cardiovascular Disease.

Authors:  Aaron J Rogers; Jessica M Miller; Ramaswamy Kannappan; Palaniappan Sethu
Journal:  IEEE Trans Biomed Eng       Date:  2019-03-18       Impact factor: 4.538

3.  Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation.

Authors:  Brittany G Durgin; Scott A Hahn; Heidi M Schmidt; Megan P Miller; Neha Hafeez; Ilka Mathar; Daniel Freitag; Peter Sandner; Adam C Straub
Journal:  JCI Insight       Date:  2019-10-03

Review 4.  Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives.

Authors:  Sabzali Javadov; Sehwan Jang; Bryan Agostini
Journal:  Pharmacol Ther       Date:  2014-06-09       Impact factor: 12.310

Review 5.  Myofilament dysfunction as an emerging mechanism of volume overload heart failure.

Authors:  Kristin Wilson; Pamela A Lucchesi
Journal:  Pflugers Arch       Date:  2014-02-01       Impact factor: 3.657

6.  Guidelines for translational research in heart failure.

Authors:  Enrique Lara-Pezzi; Philippe Menasché; Jean-Hugues Trouvin; Lina Badimón; John P A Ioannidis; Joseph C Wu; Joseph A Hill; Walter J Koch; Albert F De Felice; Peter de Waele; Valérie Steenwinckel; Roger J Hajjar; Andreas M Zeiher
Journal:  J Cardiovasc Transl Res       Date:  2015-01-21       Impact factor: 4.132

7.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Authors:  Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai
Journal:  Basic Res Cardiol       Date:  2014-12-06       Impact factor: 17.165

Review 8.  The NO/ONOO-cycle as the central cause of heart failure.

Authors:  Martin L Pall
Journal:  Int J Mol Sci       Date:  2013-11-13       Impact factor: 5.923

Review 9.  Mechanotransduction Mechanisms in Mitral Valve Physiology and Disease Pathogenesis.

Authors:  Leah A Pagnozzi; Jonathan T Butcher
Journal:  Front Cardiovasc Med       Date:  2017-12-22

10.  Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure.

Authors:  Reshma S Baliga; Michael E J Preedy; Matthew S Dukinfield; Sandy M Chu; Aisah A Aubdool; Kristen J Bubb; Amie J Moyes; Michael A Tones; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-16       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.